The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
Senate Judiciary Chairman Chuck Grassley of Iowa announced on Friday the introduction of a bill aimed at preventing opioid ...
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
Robert F. Kennedy Jr. also disclosed that he had reached at least one settlement agreement with a company or individual that ...
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental There’s a new way for doctors to treat the ...